Clinical Trials
32 trialsNCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT06053658 2026-05-20
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04987203 2026-05-08
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT06661720 2026-05-08
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04645160 2026-05-07
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT07218692 2025-10-20
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT03970616 2023-07-12
DEDUCTIVE
AVEO Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT01769885 2022-08-15
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT03136627 2021-12-06
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01853644 2021-10-12
TIVO
Northwestern University
Phase 2 Completed
NCT01835223 2020-10-28
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01297244 2020-10-27
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT01745367 2020-10-27
BATON-BC
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00502307 2020-09-01
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT01782313 2019-09-09
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Northwestern University
Phase 2 Completed
NCT01846871 2019-01-08
Tivozanib for Recurrent Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT01972516 2017-06-05
Tivozanib As Maintenance Therapy In GYN
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01058655 2017-04-13
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00970411 2017-01-05
Study of KRN951 in Patients With Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT01807156 2016-04-22
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT01478594 2015-07-08
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01306630 2014-01-27
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT01728181 2013-07-25
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
University of Utah
Phase 1/2 Withdrawn
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00660153 2012-08-28
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00717340 2012-06-28
A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00826878 2012-06-28
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00563147 2011-10-04
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT01210846 2011-09-26
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
Phase 1 Completed